Outpatient Type 2 Diabetes: The Evidence Behind the Pathway

It is a busy Thursday OPD. A 61-year-old shopkeeper from Udupi has had type 2 diabetes for 16 years. He had a heart attack four years ago. He takes metformin and glibenclamide, and his new report shows an HbA1c of 5.9%. His haemoglobin is 9.8 g/dL, and the smear suggests iron deficiency. His eGFR is 38. He is pleased with the HbA1c, and so, at first glance, are we. This is an illustrative case, not a real patient.

By the end of this article you will know why that 5.9% should worry you. You will also know what to change in his prescription today, and what to teach him before he leaves.

1. Whose Target Is It?

There is no single target of 7 per cent for everyone. The tool reads four things about the patient, and they move the target up or down:

• Below 6.5%: young (under 45 years), diabetes for under 5 years, and no ASCVD, CKD or history of hypoglycaemia.
• Below 7.0%: the standard adult with none of the modifiers.
• Below 7.5%: ASCVD or CKD present, and diabetes for more than 15 years.
• Below 8.0%: frail, aged 75 or more, a history of severe hypoglycaemia, or erratic meals.

“Why not aim low for everyone? Surely lower is better.” In a young patient with new diabetes, yes: tight control early buys a long-term benefit, the legacy effect seen in UKPDS. But in long-standing disease with damaged vessels, the trials (VADT and ACCORD) found that pushing harder gave diminishing returns and more hypoglycaemia. In the frail, a fall or an arrhythmia from a low sugar is a more immediate danger than the eye or kidney damage we are trying to prevent.

Our shopkeeper has ASCVD and 16 years of diabetes. His target is below 7.5%.

2. Below Target Is Not the Same as Well Controlled

This is the part that is easy to miss. His HbA1c of 5.9% is well below his target of 7.5%, and he is on a sulfonylurea. A patient on a sulfonylurea or insulin whose HbA1c sits well below target is having recurrent hypoglycaemia, and most of it will not have been recognised. The tool reads that as a reason to de-escalate.

On drugs that do not cause hypoglycaemia (metformin alone, for example) the tool does not, because there the low figure is not being bought at that price.

A common mistake is to congratulate this patient and repeat the prescription. It is easy to see why: a low HbA1c looks like success, and he feels well. Ask him about sweating, hunger or confusion before meals, and about waking at night. Many patients have learnt to eat a biscuit and say nothing.

3. When the HbA1c Itself Cannot Be Trusted

HbA1c measures how much of the haemoglobin has glucose stuck to it. That depends on two things: the average blood glucose, and how long each red cell has been in the circulation picking it up. The assay assumes a red cell lifespan of about 120 days.

“So what happens when the red cells live longer or shorter?” The figure drifts, and the direction tells you which way. Here is the table the tool used to carry, with the reason in its middle column:

Think of it as a sponge left out in the rain. The longer it stays out, the wetter it gets, even if the rain is no heavier. When few new red cells are being made, as in iron deficiency, the cells in the blood are older on average and carry more glucose: the HbA1c reads high. When red cells are destroyed early, as in haemolysis or after a bleed, the cells are young and the HbA1c reads low. The comparison stops at one point: the HbA1c cannot tell you which of the two is happening. The blood count and the history can.

Now return to our shopkeeper. He has iron deficiency, which pushes the HbA1c up. So his true average glucose is probably even lower than 5.9% suggests. When the HbA1c and the patient’s story disagree, check his glucose readings directly before you act on the number.

4. Combinations to Stop Today

The tool flags six combinations. Two of them apply to patients like ours every week:

• Two sulfonylureas, or a sulfonylurea with a meglitinide: additive hypoglycaemia (the second pair works on the same SUR1/Kir6.2 channel). Discontinue one immediately.
• DPP-4 inhibitor with a GLP-1 receptor agonist: the same incretin pathway twice. Discontinue the DPP-4 inhibitor.
• Pioglitazone in heart failure: fluid retention worsens heart failure, and it has been fatal. Discontinue pioglitazone.
• Saxagliptin in heart failure: more heart failure admissions (SAVOR-TIMI 53). Switch to sitagliptin or linagliptin, or an SGLT2 inhibitor.
• Glibenclamide in the elderly or in CKD: active metabolites cause hypoglycaemia that is prolonged, and that has been fatal. Switch to gliclazide MR or a DPP-4 inhibitor.

Our shopkeeper is on glibenclamide with an eGFR of 38. That combination is on the list. Glibenclamide is contraindicated in CKD; gliclazide MR is the safest sulfonylurea in CKD, and a DPP-4 inhibitor is the other choice.

5. The Kidney Decides the Dose

Every oral drug for diabetes has a renal rule. The ones you will use most:

• Metformin: contraindicated if eGFR is below 30; maximum 1000 mg a day at eGFR 30 to 45; do not start it afresh below 45.
• SGLT2 inhibitors: do not start below eGFR 20; continue for heart and kidney protection down to dialysis. The glucose-lowering effect fades below eGFR 45.
• Sitagliptin: 50 mg at eGFR 30 to 44; 25 mg below 30. Vildagliptin: 50 mg once daily below 50. Saxagliptin: 2.5 mg below 45.
• Linagliptin and teneligliptin: no dose adjustment at any eGFR.

At an eGFR of 38, his metformin must come down to 1000 mg a day at most.

6. SGLT2 Inhibitors: More Than Sugar

“His sugar is already low. Why add another drug?” Because this one is not mainly for the sugar. Dapagliflozin and empagliflozin are now approved for heart failure and CKD even without diabetes (DAPA-HF, EMPEROR-Reduced and Preserved, DAPA-CKD). Every patient with type 2 diabetes and ASCVD, heart failure or CKD should be on an SGLT2 inhibitor unless contraindicated. Our shopkeeper has two of the three, and an eGFR above 20.

Two warnings travel with the prescription. Glycosuria in a hot, humid climate invites mycotic balanoposthitis and vulvovaginitis, so counsel on genital hygiene when you write it, not when he returns with the complaint. And euglycaemic DKA: withhold the drug in acute illness, in starvation, and for 3 days before major surgery. Tell him to seek care for nausea, vomiting or abdominal pain even when his glucose is normal.

7. Drugs Made for the Indian Patient

Three drugs on the tool’s list are used far more in India than in Western textbooks.

Saroglitazar, from Zydus, is a dual PPAR-alpha and gamma agonist, given as 4 mg once daily and approved for diabetic dyslipidaemia and NASH. On its effects, the tool used to add: Reduces TG 40-50%, raises HDL, reduces hepatic fat. Unlike pioglitazone, it does not cause oedema or significant weight gain. The randomised trial behind it, PRESS V, compared it with pioglitazone 45 mg (Pai and colleagues, 2014).

Voglibose suits a meal built on rice or wheat. Given as 0.2 to 0.3 mg before meals, it blunts the post-prandial spike by 40 to 60 mg/dL.

Teneligliptin is the most prescribed DPP-4 inhibitor in India, at about ₹3 to 5 a tablet in Jan Aushadhi Kendras, and needs no renal dose adjustment. On its standing elsewhere, the tool used to say: Not US-FDA approved but has extensive Japanese/Indian post-marketing data. That is worth knowing when a patient brings you a foreign guideline that does not mention it.

8. Sick-Day Rules: Teach Every Patient

The most useful five minutes of the consultation may be the last. During acute illness, vomiting or reduced intake:

• Stop metformin (lactic acidosis), the SGLT2 inhibitor (euglycaemic DKA) and diuretics (dehydration).
• Continue the DPP-4 inhibitor and insulin (insulin may need to go up).
• Reduce the sulfonylurea: halve the dose, or skip it if not eating.
• Monitor blood glucose every 4 to 6 hours; seek help if it is above 300, if vomiting persists, or if there is ketonuria.
• Hydrate with small, frequent sips of ORS or clear fluids, 150 to 200 mL an hour.

Back to Our Patient

His target is below 7.5%. His HbA1c of 5.9% on glibenclamide means unrecognised hypoglycaemia, and his iron deficiency means the true figure is probably lower still. So we stop glibenclamide: it is contraindicated in CKD, and it is the likely cause. We reduce metformin to 1000 mg a day for his eGFR of 38. We start an SGLT2 inhibitor for his heart and kidneys, with the hygiene and sick-day advice. We treat his iron deficiency, and we read his next HbA1c knowing that it may fall further as new, young red cells arrive. Write the sick-day rules on his prescription.

Try This

A 79-year-old retired teacher, living alone and eating irregularly, has had diabetes for 8 years and has no heart or kidney disease. She is on gliclazide MR, and her HbA1c is 7.8%. Her daughter asks you to “bring it below 7”. What is her target, and what do you say? Illustrative case.

Answer. She is 75 or older and her meals are erratic, so her target is below 8.0%. At 7.8% she is within it. Pushing her below 7 on a sulfonylurea would buy little and risk falls from hypoglycaemia. Explain this to the daughter, and keep the focus on symptoms and quality of life.

Take-Home Points

• Set the HbA1c target from age, duration, ASCVD or CKD, and the risk of hypoglycaemia; there is no single 7 per cent.
• On a sulfonylurea or insulin, an HbA1c well below target means hypoglycaemia until proved otherwise: de-escalate.
• Iron deficiency pushes the HbA1c up; haemolysis, blood loss and late pregnancy push it down.
• Stop glibenclamide in the elderly and in CKD, and check every drug against the eGFR.
• Offer an SGLT2 inhibitor in ASCVD, heart failure or CKD, and teach the sick-day rules to everyone.

For how the tool sets the target, see The HbA1c Target: The Evidence Behind the Tool; for diagnosis, Diagnosing Diabetes and Prediabetes: The Evidence Behind the Thresholds and Diabetes Classification: The Evidence Behind the Pathway; and for the plate, The Smart Plate: How to Eat Well With Diabetes, the Indian Way.

Declaration: the author built and maintains the tool. It is free to use. The figures in this article are those the tool carried in its Evidence tab on 5 November 2026, each from the source the tool names. The illustrative cases follow the tool’s rules; check the tool’s result for a real patient.

References

1. RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022. Int J Diabetes Dev Ctries. 2022;42(Suppl 1).
2. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1). [Current edition]
3. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127.
4. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29(2):388-394.
5. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117-2128.
6. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
7. McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995-2008.
8. Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446.
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin. Lancet. 1998;352(9131):854-865.
10. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
11. Pai V, Paneerselvam A, Mukhopadhyay S, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014;8(1):132-141. PMID 24876549.
12. Anjana RM, et al. ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585-596.
13. ICMR Guidelines for Management of Type 2 Diabetes 2018.